Orzan, O.A.; Țieranu, C.G.; Olteanu, A.O.; Dorobanțu, A.M.; Cojocaru, A.; Mihai, M.M.; Popa, L.G.; Gheorghiu, A.M.; Giurcăneanu, C.; Ion, A.
An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients. Pharmaceutics 2023, 15, 2171.
https://doi.org/10.3390/pharmaceutics15082171
AMA Style
Orzan OA, Țieranu CG, Olteanu AO, Dorobanțu AM, Cojocaru A, Mihai MM, Popa LG, Gheorghiu AM, Giurcăneanu C, Ion A.
An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients. Pharmaceutics. 2023; 15(8):2171.
https://doi.org/10.3390/pharmaceutics15082171
Chicago/Turabian Style
Orzan, Olguța Anca, Cristian George Țieranu, Andrei Ovidiu Olteanu, Alexandra Maria Dorobanțu, Anca Cojocaru, Mara Mădălina Mihai, Liliana Gabriela Popa, Ana Maria Gheorghiu, Călin Giurcăneanu, and Ana Ion.
2023. "An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients" Pharmaceutics 15, no. 8: 2171.
https://doi.org/10.3390/pharmaceutics15082171
APA Style
Orzan, O. A., Țieranu, C. G., Olteanu, A. O., Dorobanțu, A. M., Cojocaru, A., Mihai, M. M., Popa, L. G., Gheorghiu, A. M., Giurcăneanu, C., & Ion, A.
(2023). An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients. Pharmaceutics, 15(8), 2171.
https://doi.org/10.3390/pharmaceutics15082171
